Innovent Transfers CAR T-Cell Treatment to IASO Bio

The licence for Fucaso, a chimeric antigen receptor (CAR) T-cell treatment, has been transferred by Innovent Biologics to its research and manufacturing partner IASO Biotechnology.

The deal’s purchase price was kept a secret by the parties, despite Innovent saying it was going to utilise the money to buy an 18% share in IASO Bio. IASO Bio now has the worldwide commercial rights to Fucaso as a result of the transaction.

A B-cell maturation antigen (BCMA) that targets CAR T-cell treatment is called fucaso. Just recently, the National Medical Products Administration (NMPA) of China authorised it as a fourth-line treatment for relapsed and/or refractory multiple myeloma (r/r MM).

Additionally, Fucaso has an IND authorization and has been designated by the FDA as an orphan medication, medically advanced therapy, and fast track for the treatment of r/r MM.

According to a sales and forecast database, the industry for cell and gene therapy is expected to be valued approximately $81 billion by 2029. Following the FDA’s November 2023 start of a safety investigation into CAR-T cell treatments, the industry has also come under further scrutiny.